[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.90.95. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Original Article
April 1992

Clinical Experiments in Maintenance and Discontinuation of Imipramine Therapy in Panic Disorder With Agoraphobia

Author Affiliations

From the Department of Psychiatry, The Ohio State University College of Medicine, Columbus (Dr Mavissakalian), and the Clinical Pharmacology Program, University of Pittsburgh (Pa) School of Medicine (Dr Perel).

Arch Gen Psychiatry. 1992;49(4):318-323. doi:10.1001/archpsyc.49.4.318
Abstract

Several issues remain to be ascertained beyond the acute response to imipramine hydrochloride in patients with panic disorder. Study 1 consisted of a prospective, systematic characterization of half-dose 12-month maintenance in patients with panic disorder with agoraphobia who had shown marked and stable response to 6 months of acute-phase treatment with imipramine. Study 2 assessed the 6-month cumulative relapse rate following discontinuation of acute-phase imipramine treatment in a comparable sample of patients. The same assessment battery was used in both studies, and the integrity of experimental drug conditions was verified by plasma drug level determinations. In contrast to the high relapse rate following discontinuation of acute-phase treatment, none of the patients showed relapse or had sustained worsening in panic or phobia measures during the half-dose maintenance period. The results underscore the importance of pharmacological prophylaxis and provide empirical guidelines for a successful low-dose maintenance regimen for patients with panic disorder and agoraphobia who respond markedly to imipramine.

×